Cogent Biosciences Inc

COGT remains in a Stage 2 advancing corrective reset within an uptrend. The late-July Bullish Exhaustion highlights weakening upside momentum, leading to a pullback into the rising EMAs. Medium-term bias stays bullish as price holds above the rising 50DMA with higher highs and higher lows intact. Execution should be patient, accumulating on shallow, absorbed pullbacks into the 9/20 EMA area.

• ↑NDA filed for Bezuclastinib in systemic mastocytosis; approval could drive major revenue
• ↑High growth factor suggests robust pipeline and market potential
• ↓Negative profitability factors signal ongoing losses and inefficiencies